KURA ONCOLOGY INC (KURA) Stock Price, Quote, News and Overview
NASDAQ:KURA - Nasdaq - US50127T1097 - Common Stock - Currency: USD
KURA Quote, Performance and Key Statistics
KURA ONCOLOGY INC
NASDAQ:KURA (1/29/2025, 8:00:02 PM)
Premarket: 7.11 -0.58 (-7.54%)7.69
-0.08 (-1.03%)
The current stock price of KURA is 7.69 USD. In the past month the price decreased by -11.3%. In the past year, price decreased by -63.61%.
KURA Latest News, Press Releases and Analysis
Kura Oncology Announces Senior Executive Promotions
– Mollie Leoni, M.D. promoted to Chief Medical Officer – – Francis Burrows, Ph.D. promoted to Chief Scientific Officer – – Stephen Dale, M.D., steps down...
Kura Oncology and Kyowa Kirin Report Positive Combination Data for Ziftomenib at American Society of Hematology Annual Meeting
– Interim analysis from Phase 1a portion of KOMET-007 shows 100% CR rate in NPM1-m and 83% CR rate in KMT2A-r 1L adverse risk AML with 7+3 – – 100% of 1L...
Kura Oncology to Host Virtual Investor Event on December 9, 2024
Live webcast and conference call to discuss presentation of updated data from KOMET-007 combination trial of ziftomenib at ASH...
Kura Oncology to Participate in JMP Securities Hematology and Oncology Summit
SAN DIEGO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the...
KURA Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 16.3 | 309.71B | ||
| AMGN | AMGEN INC | 14.66 | 151.41B | ||
| GILD | GILEAD SCIENCES INC | 21.58 | 119.13B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 865.73 | 113.70B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.13 | 75.52B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.15B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 35.34B | ||
| BNTX | BIONTECH SE-ADR | N/A | 29.20B | ||
| ONC | BEIGENE LTD-ADR | N/A | 24.14B | ||
| NTRA | NATERA INC | N/A | 22.21B | ||
| BIIB | BIOGEN INC | 8.84 | 21.04B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.37 | 16.64B |
Related stock screener links
About KURA
Company Profile
Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. The company is headquartered in San Diego, California and currently employs 142 full-time employees. The company went IPO on 2015-11-05. The firm is focused on precision medicine for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer signaling pathways. Its product candidates include Ziftomenib, Tipifarnib and KO-2806. Ziftomenib, is a potent, selective, reversible and oral small molecule inhibitor that blocks the interaction of two proteins, menin and the protein expressed by the Lysine K-specific Methyl Transferase 2A gene, or KMT2A gene. Ziftomenib is a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction for the treatment of genetically defined acute myeloid leukemia patients with high unmet need. Tipifarnib is a potent, selective and orally bioavailable farnesyl transferase inhibitor (FTI). The KO-2806 is a next-generation FTI, which demonstrates improved potency, pharmacokinetic and physicochemical properties relative to earlier FTI drug candidates.
Company Info
KURA ONCOLOGY INC
12730 High Bluff Drive, Suite 400
San Diego CALIFORNIA 92130 US
CEO: Troy E. Wilson
Employees: 142
Company Website: https://www.kuraoncology.com/
Investor Relations: https://ir.kuraoncology.com/
Phone: 18585008800
KURA FAQ
What is the stock price of KURA?
The current stock price of KURA is 7.69 USD.
What is the symbol for KURA ONCOLOGY INC stock?
The exchange symbol of KURA ONCOLOGY INC is KURA and it is listed on the Nasdaq exchange.
On which exchange is KURA stock listed?
KURA stock is listed on the Nasdaq exchange.
Is KURA a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for KURA, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of KURA.
Does KURA stock pay dividends?
KURA does not pay a dividend.
When does KURA stock report earnings?
KURA will report earnings on 2025-02-20, after the market close.
What is the Price/Earnings (PE) ratio of KURA?
KURA does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.36).
What is the Short Interest ratio of KURA stock?
The outstanding short interest for KURA is 13.9% of its float.
KURA Technical Analysis
KURA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to KURA. The financial health of KURA is average, but there are quite some concerns on its profitability.
KURA Financial Highlights
Over the last trailing twelve months KURA reported a non-GAAP Earnings per Share(EPS) of -2.36. The EPS decreased by -16.83% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -41.26% | ||
| ROE | -46.62% | ||
| Debt/Equity | 0.02 |
KURA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 84% to KURA. The Buy consensus is the average rating of analysts ratings from 22 analysts.